Display options
Cite
Brieger KK, Phung MT, Mukherjee B, et al. High Prediagnosis Inflammation-Related Risk Score Associated with Decreased Ovarian Cancer Survival. Cancer Epidemiol Biomarkers Prev. 2021;doi: 10.1158/1055-9965.EPI-21-0977.
Brieger, K. K., Phung, M. T., Mukherjee, B., Bakulski, K. M., Anton-Culver, H., Bandera, E. V., Bowtell, D. D. L., Cramer, D. W., DeFazio, A., Doherty, J. A., Fereday, S., Fortner, R. T., Gentry-Maharaj, A., Goode, E. L., Goodman, M. T., Harris, H. R., Matsuo, K., Menon, U., Modugno, F., Moysich, K. B., Qin, B., Ramus, S. J., Risch, H. A., Rossing, M. A., Schildkraut, J. M., Trabert, B., Vierkant, R. A., Winham, S. J., Wentzensen, N., Wu, A. H., Ziogas, A., Khoja, L., Cho, K. R., McLean, K., Richardson, J., Grout, B., Chase, A., Deurloo, C. M., Odunsi, K., Nelson, B. H., Brenton, J. D., Terry, K. L., Pharoah, P. D. P., Berchuck, A., Hanley, G. E., Webb, P. M., Pike, M. C., Pearce, C. L. (2021). High Prediagnosis Inflammation-Related Risk Score Associated with Decreased Ovarian Cancer Survival. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, . https://doi.org/10.1158/1055-9965.EPI-21-0977
Brieger, Katharine K, et al. "High Prediagnosis Inflammation-Related Risk Score Associated with Decreased Ovarian Cancer Survival." Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology vol. (2021). doi: https://doi.org/10.1158/1055-9965.EPI-21-0977
Brieger KK, Phung MT, Mukherjee B, Bakulski KM, Anton-Culver H, Bandera EV, Bowtell DDL, Cramer DW, DeFazio A, Doherty JA, Fereday S, Fortner RT, Gentry-Maharaj A, Goode EL, Goodman MT, Harris HR, Matsuo K, Menon U, Modugno F, Moysich KB, Qin B, Ramus SJ, Risch HA, Rossing MA, Schildkraut JM, Trabert B, Vierkant RA, Winham SJ, Wentzensen N, Wu AH, Ziogas A, Khoja L, Cho KR, McLean K, Richardson J, Grout B, Chase A, Deurloo CM, Odunsi K, Nelson BH, Brenton JD, Terry KL, Pharoah PDP, Berchuck A, Hanley GE, Webb PM, Pike MC, Pearce CL. High Prediagnosis Inflammation-Related Risk Score Associated with Decreased Ovarian Cancer Survival. Cancer Epidemiol Biomarkers Prev. 2021 Nov 17; doi: 10.1158/1055-9965.EPI-21-0977. Epub 2021 Nov 17. PMID: 34789471.
Copy Download .nbib Format: NLM
Share it on

Cancer Epidemiol Biomarkers Prev. 2021 Nov 17; doi: 10.1158/1055-9965.EPI-21-0977. Epub 2021 Nov 17.

High Prediagnosis Inflammation-Related Risk Score Associated with Decreased Ovarian Cancer Survival.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

Katharine K Brieger, Minh Tung Phung, Bhramar Mukherjee, Kelly M Bakulski, Hoda Anton-Culver, Elisa V Bandera, David D L Bowtell, Daniel W Cramer, Anna DeFazio, Jennifer A Doherty, Sian Fereday, Renée Turzanski Fortner, Aleksandra Gentry-Maharaj, Ellen L Goode, Marc T Goodman, Holly R Harris, Keitaro Matsuo, Usha Menon, Francesmary Modugno, Kirsten B Moysich, Bo Qin, Susan J Ramus, Harvey A Risch, Mary Anne Rossing, Joellen M Schildkraut, Britton Trabert, Robert A Vierkant, Stacey J Winham, Nicolas Wentzensen, Anna H Wu, Argyrios Ziogas, Lilah Khoja, Kathleen R Cho, Karen McLean, Jean Richardson, Bronwyn Grout, Anne Chase, Cindy McKinnon Deurloo, Kunle Odunsi, Brad H Nelson, James D Brenton, Kathryn L Terry, Paul D P Pharoah, Andrew Berchuck, Gillian E Hanley, Penelope M Webb, Malcolm C Pike, Celeste Leigh Pearce,

Affiliations

  1. Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, Michigan.
  2. Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, Michigan.
  3. Department of Medicine, School of Medicine, University of California Irvine, Irvine, California.
  4. Cancer Epidemiology and Health Outcomes, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey.
  5. Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  6. Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
  7. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
  8. Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
  9. Centre for Cancer Research, The Westmead Institute for Medical Research, and The University of Sydney, Westmead, New South Wales, Australia.
  10. Department of Gynaecological Oncology, Westmead Hospital, Westmead, New South Wales, Australia.
  11. Department of Population Health Sciences, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, Utah.
  12. Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  13. MRC Clinical Trials Unit, Institute of Clinical Trials & Methodology, UCL, London, United Kingdom.
  14. Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota.
  15. Cancer Prevention and Genetics Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California.
  16. Community and Population Health Research Center, Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California.
  17. Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington.
  18. Department of Epidemiology, University of Washington School of Public Health, Seattle, Washington.
  19. Division of Cancer Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Japan.
  20. Department of Cancer Epidemiology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  21. Women's Cancer Research Center, Magee-Women's Research Institute and UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania.
  22. Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
  23. Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, Pittsburgh, Pennsylvania.
  24. Division of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, New York.
  25. School of Women's and Children's Health, Faculty of Medicine, University of NSW Sydney, Sydney, New South Wales, Australia.
  26. Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia.
  27. Chronic Disease Epidemiology Department, Yale School of Public Health, New Haven, Connecticut.
  28. Emory University Rollins School of Public Health, Atlanta, Georgia.
  29. Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland.
  30. Division of Clinical Trials and Biostatistics, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota.
  31. Division of Computational Biology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota.
  32. Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California.
  33. Department of Pathology, Michigan Medicine, University of Michigan, Ann Arbor, Michigan.
  34. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Michigan Medicine, University of Michigan, Ann Arbor, Michigan.
  35. Patient Advocate.
  36. University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois.
  37. Deeley Research Centre, British Columbia Cancer Agency, Victoria, British Columbia, Canada.
  38. Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
  39. Department of Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, United Kingdom.
  40. Department of Public Health and Primary Care, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, United Kingdom.
  41. Division of Gynecologic Oncology, Duke University School of Medicine, Durham, North Carolina.
  42. Department of Obstetrics & Gynecology, University of British Columbia Faculty of Medicine, Vancouver, British Columbia, Canada.
  43. Department of Population Health, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
  44. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.

PMID: 34789471 DOI: 10.1158/1055-9965.EPI-21-0977

Abstract

BACKGROUND: There is suggestive evidence that inflammation is related to ovarian cancer survival. However, more research is needed to identify inflammation-related factors that are associated with ovarian cancer survival and to determine their combined effects.

METHODS: This analysis used pooled data on 8,147 women with invasive epithelial ovarian cancer from the Ovarian Cancer Association Consortium. The prediagnosis inflammation-related exposures of interest included alcohol use; aspirin use; other nonsteroidal anti-inflammatory drug use; body mass index; environmental tobacco smoke exposure; history of pelvic inflammatory disease, polycystic ovarian syndrome, and endometriosis; menopausal hormone therapy use; physical inactivity; smoking status; and talc use. Using Cox proportional hazards models, the relationship between each exposure and survival was assessed in 50% of the data. A weighted inflammation-related risk score (IRRS) was developed, and its association with survival was assessed using Cox proportional hazards models in the remaining 50% of the data.

RESULTS: There was a statistically significant trend of increasing risk of death per quartile of the IRRS [HR = 1.09; 95% confidence interval (CI), 1.03-1.14]. Women in the upper quartile of the IRRS had a 31% higher death rate compared with the lowest quartile (95% CI, 1.11-1.54).

CONCLUSIONS: A higher prediagnosis IRRS was associated with an increased mortality risk after an ovarian cancer diagnosis. Further investigation is warranted to evaluate whether postdiagnosis exposures are also associated with survival.

IMPACT: Given that pre- and postdiagnosis exposures are often correlated and many are modifiable, our study results can ultimately motivate the development of behavioral recommendations to enhance survival among patients with ovarian cancer.

©2021 American Association for Cancer Research.

Publication Types